PE20001386A1 - COMBINATION THERAPY FOR HCV BY INDUCTION OF RIBAVIRIN-INTERFERON ALPHA - Google Patents

COMBINATION THERAPY FOR HCV BY INDUCTION OF RIBAVIRIN-INTERFERON ALPHA

Info

Publication number
PE20001386A1
PE20001386A1 PE1999001294A PE00129499A PE20001386A1 PE 20001386 A1 PE20001386 A1 PE 20001386A1 PE 1999001294 A PE1999001294 A PE 1999001294A PE 00129499 A PE00129499 A PE 00129499A PE 20001386 A1 PE20001386 A1 PE 20001386A1
Authority
PE
Peru
Prior art keywords
interferon alpha
miu
weeks
ribavirin
combination therapy
Prior art date
Application number
PE1999001294A
Other languages
Spanish (es)
Inventor
Janice K Albrecht
Paul W Glue
Carlos Olgierd Stalgis
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20001386A1 publication Critical patent/PE20001386A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Abstract

SE REFIERE A EL USO DE RIVABIRINA EN ASOCIACION CON INTERFERON ALFA EN DOS PERIODOS DE TRATAMIENTO: a) 800-1200mg/DIA DE RIVABIRINA MAS INTERFERON ALFA ADMINISTRANDO 10 MIU DURANTE 2 SEMANAS SEGUIDO DE 5 MIU POR 6 SEMANAS, SEGUIDO DE 3 MIU POR 16 SEMANAS PARA DISMINUIR EL NIVEL DE ARN DE VHC DETECTABLE; b)800-1200mg/DIA DE RIBAVIRINA MAS 3 MIU DE INTERFERON ALFA POR UN PERIODO DE 20 A 30 SEMANAS PARA ERRADICAR EL ARN DEL VHC DETECTABLE. EL INTERFERON ALFA ES SELECCIONADO DE INTERFERON ALFA-2a, INTERFERON ALFA-2b, INTERFERON DE CONSENSO, PRODUCTO DE INTERFERON ALFA PURIFICADO. LA TERAPIA DE COMBINACION ES UTIL EN PACIENTES CON HEPATITIS C CRONICA INFECTADOS CON GENOTIPOS DE VHC MULTIPLE TIPO 1, 2 Y 3REFERS TO THE USE OF RIVABIRIN IN ASSOCIATION WITH INTERFERON ALPHA IN TWO PERIODS OF TREATMENT: a) 800-1200mg / DAY OF RIVABIRIN PLUS INTERFERON ALPHA ADMINISTERING 10 MIU FOR 2 WEEKS FOLLOWED BY 5 MIU FOR 6 WEEKS, FOLLOWED BY 3 MIU FOR 16 WEEKS TO REDUCE DETECTABLE HCV RNA LEVEL; b) 800-1200mg / DAY OF RIBAVIRIN PLUS 3 MIU OF ALPHA INTERFERED FOR A PERIOD OF 20 TO 30 WEEKS TO ERADICATE DETECTABLE HCV RNA. THE INTERFERON ALPHA IS SELECTED FROM INTERFERON ALPHA-2a, INTERFERON ALPHA-2b, INTERFERON OF CONSENSUS, INTERFERON ALPHA PURIFIED PRODUCT. COMBINATION THERAPY IS USEFUL IN PATIENTS WITH CHRONIC HEPATITIS C INFECTED WITH MULTIPLE HCV TYPE 1, 2 AND 3 GENOTYPES

PE1999001294A 1998-12-18 1999-12-17 COMBINATION THERAPY FOR HCV BY INDUCTION OF RIBAVIRIN-INTERFERON ALPHA PE20001386A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21587598A 1998-12-18 1998-12-18

Publications (1)

Publication Number Publication Date
PE20001386A1 true PE20001386A1 (en) 2000-12-14

Family

ID=22804763

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001294A PE20001386A1 (en) 1998-12-18 1999-12-17 COMBINATION THERAPY FOR HCV BY INDUCTION OF RIBAVIRIN-INTERFERON ALPHA

Country Status (4)

Country Link
AR (1) AR022116A1 (en)
AU (1) AU2156900A (en)
PE (1) PE20001386A1 (en)
WO (1) WO2000037097A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
WO2006016657A1 (en) 2004-08-11 2006-02-16 Chugai Seiyaku Kabushiki Kaisha Drug for treating or preventing hcv infection
US7723310B2 (en) 2004-10-18 2010-05-25 Three Rivers Pharmaceuticals, Llc Large dose ribavirin formulations
CA2652333A1 (en) * 2006-05-16 2007-11-22 Tokyo Metropolitan Organization For Medical Research Pharmaceutical composition for treating or preventing hcv infection
EP1977759A1 (en) * 2007-03-27 2008-10-08 4Sc Ag Pharmaceutical composition comprising a cytokine
WO2008116919A1 (en) * 2007-03-27 2008-10-02 4Sc Ag Pharmaceutical composition comprising a cytokine
US20110270212A1 (en) * 2007-10-05 2011-11-03 Medtronic, Inc. Pharmacokinetic control for optimized interferon delivery
EP2610343A3 (en) 2008-11-26 2013-09-25 Chugai Seiyaku Kabushiki Kaisha Method for designing siRNA and oligoribonucleotides inhibiting HCV
DE202012013117U1 (en) 2011-10-21 2015-01-16 Abbvie Inc. Combination treatment (e.g., with ABT-072 or ABT-333 from DAAs for use in the treatment of HCV)
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE112012003510T5 (en) 2011-10-21 2015-03-19 Abbvie Inc. Method for the treatment of HCV comprising at least two direct-acting antiviral agents, ribavirin but not interferon
CN109689063A (en) 2016-04-28 2019-04-26 埃默里大学 Nucleotide containing alkynes and nucleosides therapeutic combination and its associated uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
EP0903148B1 (en) * 1997-09-21 2001-10-10 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection

Also Published As

Publication number Publication date
AR022116A1 (en) 2002-09-04
WO2000037097A1 (en) 2000-06-29
AU2156900A (en) 2000-07-12

Similar Documents

Publication Publication Date Title
NZ507621A (en) HCV-RNA eradication in antiviral treatment naive patients having HCV genotypes 1, 2 or 3 using ribavirin and interferon alpha combination therapy
AR021876A1 (en) COMBINATION THERAPY FOR HCV INDUCTION OF RIBAVIRINA - INTERFERON ALFA PEGILADO
BR0009840A (en) Combination therapy for hcv, containing ribavirin in combination with antioxidants
ES2186660T3 (en) COMBINATION THERAPY TO ERADICATE HCV-RNA DETECTABLE IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION.
BR9809425A (en) Alpha interferon-polyethylene glycol conjugates for infection therapy
BR0114636A (en) Pegylated interferon-alpha / ribavirin hcv combination therapy
PE20001386A1 (en) COMBINATION THERAPY FOR HCV BY INDUCTION OF RIBAVIRIN-INTERFERON ALPHA
DK0911033T3 (en) Use of consensus interferon to reduce the side effects of interferon therapy in viral hepatitis
BR0010593A (en) Combination therapy with pegylated ccr5-interferon alpha antagonist for hiv
TR200101085T2 (en) Combined ribavirin-interferon alpha therapy for the elimination of detectable HCV-RNA in patients with chronic hepatitis C infection
BR0108997A (en) Adjuvant Immune Therapy for HIV
MD1875F1 (en) Method of treatment of the acute viral hepatitis B
BRPI0409711A (en) treatment or prevention of viral respiratory infections with alpha thymosin peptides
AR029337A1 (en) USE OF INTERFERON ALFA PEGILADO FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THERAPY AGAINST HIV
MXPA05007901A (en) Hcv combination therapy.
NZ587372A (en) Treatment of bacterial, protozoan infections and cancer with a mixture of at least three different human interferon alpha proteins
HK1055689A1 (en) Treatment of hepatitis c with thymosin, interferonand ribavirin
TH46769A (en) HCV co-treatment
AU8716001A (en) Treatment of hepatitis c with thymosin and pegylated interferon
ECSP003446A (en) COMBINATION THERAPY FOR HCV
ECSP982669A (en) COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HETATITIS C INFECTION

Legal Events

Date Code Title Description
FC Refusal